Overview

Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma

Status:
Unknown status

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

The role of transarterial chemoembolization (TACE) as the standard therapy for intermediate-stage hepatocellular carcinoma (HCC) is being challenged by increasing studies which showed that liver resection (LR) is a safe and feasible procedure with better survival outcomes than TACE does. In light of this, the investigators have constructed a Markov model to simulate comparing LR and TACE in the treatment of intermediate-stage HCC. The results suggested that LR may provide survival benefit over TACE for the treatment of intermediate-stage HCC in cirrhotic patients. However, validating the simulated result by a study with higher quality (e.g. prospective clinical trial) would be of great value in providing a more convincing finding. Therefore, based on the established Markov model, the investigators aimed to prospectively compare the treatment efficacy and safety of LR with TACE for consecutive patients with intermediate-stage HCC.

Phase:

Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Antineoplastic Agents
Carboplatin
Cisplatin
Doxorubicin
Epirubicin
Ethiodized Oil
Fluorouracil
Gelatin Sponge, Absorbable
Liver Extracts
Pirarubicin